



Serology-based Total Antibody Detection Rapid Tests COVID-19 (Lateral Flow Devices)

At the end of 2019, an outbreak of the novel identified SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus 2) spread worldwide and has now been designated a pandemic by the WHO.

Rapid antibodies testing provide information in 10 minutes about past exposure to SARS-CoV-2 and do not require special laboratory equipment. This is the method of choice for rapid screening while increasing the ability to prevent the spread of infection, and a complementary tool to the direct detection of the pathogen.

COVID-19 Rapid Testing Solution

The COVID-19 total antibody detection lateral flow devices or rapid tests from Eurofins Ingenasa provide a quick solution to determine past exposure to COVID-19.

The INgezim COVID 19 CROM rapid tests are dual recognition immunochromatographic assays for detecting IgG, IgA and IgM antibodies specific to SARS-CoV-2 in blood, serum or plasma samples, with high sensitivity and specificity.

Serology-based Total Antibody Detection Rapid Tests COVID-19



Application

The **INgezim® COVID 19 CROM** is designed to qualitatively determine the total antibodies specific for the SARS-CoV-2 virus N protein in human serum or blood samples.

This is a rapid, point-of-care test, in other words, it can be carried out outside the laboratory. In the EU, these point-of-care diagnostic tests for COVID-19 are intended for use by health professionals as it is NOT for self-diagnosis.

Principles of the Tests

The test is based on the use of coloured latex microspheres bonded to the proteins of interest: the black particles are covalently bound to the N protein of SARS-CoV-2, and the blue particles to a control protein, to indicate that the immunochromatography develops correctly. If SARS-CoV-2 antibodies are present in the sample, they will react with the black latex particles coated with the N protein.



Key Benefits of the INgezim COVID 19 CROM Rapid Tests

- Results in only 10 minutes
- High specificity and sensitivity, the assay detects antibodies in **94.5% of cases from day 19 after symptoms onset**. The diagnostics **specificity is 99.3%.***
- No cross-reactivity with antibodies specific for other coronaviruses or agents related to human respiratory illnesses
- Includes all the material needed to perform the test (test strip, lancet, pipette and diluent)
- Without blood extraction, fingerprick
- CE-IVD marked

**Validation study in May 2020; to determine the diagnostic specificity, 146 sera previously classified as: (1) positive by PCR and negative by serology, (2) negative by PCR and serology, or (3) historically negative (prior to 2019) were analysed. To determine the ability of the assay to detect antibodies during an infection, 153 human sera were tested, extracted on different days after the first day the symptoms appeared.*

Art. No.	Product	No. of tests	Product description
50.CoV.K.41	INgezim COVID 19 CROM	25	Immunochromatography for determination of total antibodies in blood and serum samples.
50.CoV.K.41/S	INgezim COVID 19 CROM Easy	25	Immunochromatography strips for determination of total antibodies in blood and serum samples. (Easy)



ELISA Kit also available:

Double recognition ELISA for the determination of total antibodies to SARS-CoV-2 in serum samples. Please contact us for further information on our ELISA assay.